{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:53:08Z","timestamp":1791827588325,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Behav Health Serv Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s11414-025-09975-x","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:32:25Z","timestamp":1760887945000},"page":"677-685","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Implementation Science Assessment of Intranasal Esketamine\u2019s Limited Integration into Mainstream Psychiatric Treatment"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3646-9155","authenticated-orcid":false,"given":"Benjamin","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"O\u2019Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,19]]},"reference":[{"key":"9975_CR1","doi-asserted-by":"publisher","unstructured":"Hasin D, Sarvet A, Meyers J, Saha, T, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and its specifiers in the United States. JAMA Psychiatry, 2018;75(4):336\u2013346. Available at https:\/\/https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4602. Accessed 23 September, 2025.","DOI":"10.1001\/jamapsychiatry.2017.4602"},{"key":"9975_CR2","doi-asserted-by":"publisher","unstructured":"Murray C, Atkinson C, Bhalla K, et al. The state of US health, 1990\u20132010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591\u2013608. Available at https:\/\/https:\/\/doi.org\/10.1001\/jama.2013.13805. Accessed 10 March, 2025.","DOI":"10.1001\/jama.2013.13805"},{"key":"9975_CR3","doi-asserted-by":"publisher","unstructured":"Greenberg P, Chitnis A, Louie D. The economic burden of adults with major depressive disorder in the United States (2019). Advances in Therapy, 2023; 70: 1128\u20131137. Available at https:\/\/https:\/\/doi.org\/10.1007\/s12325-023-02622-x.\u00a0Accessed 23 September, 2025.","DOI":"10.1007\/s12325-023-02622-x"},{"key":"9975_CR4","doi-asserted-by":"publisher","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 2006;163(11):1905\u20131917. Available at https:\/\/https:\/\/doi.org\/10.1176\/ajp.2006.163.11.1905. Accessed 1 February, 2025.","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"9975_CR5","doi-asserted-by":"publisher","unstructured":"Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: A matched-cohort study using a US commercial claims base. Journal of Clinical Psychiatry 2018;79(2):24\u201333. Available at https:\/\/https:\/\/doi.org\/10.4088\/JCP.17m11725. Accessed 1 February, 2025.","DOI":"10.4088\/JCP.17m11725"},{"key":"9975_CR6","doi-asserted-by":"publisher","unstructured":"Feldman RL, Dunner DL, Muller JS, et al. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. Journal of Medical Economics, 2013;16(1):62\u201374. Available at https:\/\/https:\/\/doi.org\/10.3111\/13696998.2012.724745. Accessed 1 February, 2025.","DOI":"10.3111\/13696998.2012.724745"},{"key":"9975_CR7","doi-asserted-by":"publisher","unstructured":"Kern D, Canuso C, Daly E, et al. Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone. Brain and Behavior, 2023;13(8): e3171. Available at https:\/\/https:\/\/doi.org\/10.1002\/brb3.3171. Accessed 5 February, 2025.","DOI":"10.1002\/brb3.3171"},{"key":"9975_CR8","doi-asserted-by":"publisher","unstructured":"Popova V, Daly E, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined with a Newly Initiated Oral Antidepressant in Treatment Resistant Depression: A Randomized Double Blind Active Control Study. American Journal of Psychiatry, 2019;176:428\u2013438. Available at https:\/\/https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172. Accessed 5 February, 2025.","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"9975_CR9","doi-asserted-by":"publisher","unstructured":"Daly E, Trivedi, M, Janik A, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment in Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019;76(9):893\u2013903. Available at https:\/\/https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189. Accessed 10 February, 2025.","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"9975_CR10","doi-asserted-by":"publisher","unstructured":"Singh B, Kung S, Pazdernik V et al. Comparative effectiveness of intravenous ketamine and intranasal esketamine in real-world setting among patients with treatment refractory depression: An observational study. Journal of Clinical Psychiatry, 2023 Feb 1;84(2):22m14548. Available at https:\/\/https:\/\/doi.org\/10.4088\/JCP.22m14548. Accessed 5 February, 2025.","DOI":"10.4088\/JCP.22m14548"},{"key":"9975_CR11","doi-asserted-by":"publisher","unstructured":"D\u2019Andrea G, Pettorruso M, Di Lorenzo G, et al. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: a post-hoc analysis of pooled real-world data. Journal of Affective Disorders, 2024;348:314\u2013322. Available at https:\/\/https:\/\/doi.org\/10.1016\/j.jad.2023.12.038. Accessed 10 February, 2025.","DOI":"10.1016\/j.jad.2023.12.038"},{"key":"9975_CR12","doi-asserted-by":"publisher","unstructured":"Samalin L, Mekaoui L, Rotharmel M. Use of esketamine nasal spray in patients with treatment-resistant depression in routine practice: a real-world French study. Depression and Anxiety, 2024:7262794. Available at https:\/\/https:\/\/doi.org\/10.1155\/2024\/7262794. Accessed 1 March, 2025.","DOI":"10.1155\/2024\/7262794"},{"key":"9975_CR13","doi-asserted-by":"publisher","unstructured":"Hopwood M, Scott E, Codyre D, et al. A real-world study examining the impact of esketamine nasal spray in people living with major depressive disorder in Australia and New Zealand. Psychiatry Research Communications, 2024;4. Available at https:\/\/doi.org\/10.1016\/j.psycom.2024.100177. Accessed 3 March, 2025.","DOI":"10.1016\/j.psycom.2024.100177"},{"key":"9975_CR14","doi-asserted-by":"publisher","unstructured":"Kircher J, Smith J, Powell B, et al. Getting clinical innovation into practice: an introduction to implementation strategies. Psychiatry Research, 2020; 283:1\u20136. Available at https:\/\/https:\/\/doi.org\/10.1016\/j.psychres.2019.06.042. Accessed 3, March, 2025.","DOI":"10.1016\/j.psychres.2019.06.042"},{"key":"9975_CR15","doi-asserted-by":"publisher","unstructured":"Damschroder L, Aaron D, Keith R, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Science, 2009;4:50. Available at https:\/\/https:\/\/doi.org\/10.1186\/1748-5908-4-50. Accessed 23 January, 2025.","DOI":"10.1186\/1748-5908-4-50"},{"key":"9975_CR16","unstructured":"Consolidated framework for implementation research. Available at https:\/\/cfirguide.org\/. Accessed 15 November, 2024."},{"key":"9975_CR17","unstructured":"McCarthy J. Big pharma sinks to bottom of U.S. industry rankings. Available at https:\/\/news.gallup.com\/poll\/266060\/big-pharma-sinks-bottom-industry-rankings.aspx. Accessed 15, November, 2024."},{"key":"9975_CR18","unstructured":"PubChem Compound Summary for CID 6468, Phencyclidine. Bethesda, Maryland: National Center for Biotechnology Information. Available at\u00a0https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Phencyclidine. Accessed 22 July, 2021."},{"key":"9975_CR19","unstructured":"PubChem Compound Summary for CID 3821, Ketamine. Bethesda, Maryland: National Center for Biotechnology Information. Available at\u00a0https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ketamine. Accessed 22 July, 2021."},{"key":"9975_CR20","doi-asserted-by":"publisher","unstructured":"Sassano-Higgins S, Baron D, Juarez G, et al. A Review of Ketamine Abuse and Division. Depression and Anxiety, 2016;33:718\u2013727. Available at https:\/\/https:\/\/doi.org\/10.1002\/da.22536.\u00a0Epub 2016 Jun 22. Accessed 12 December, 2024.","DOI":"10.1002\/da.22536"},{"key":"9975_CR21","unstructured":"SPRAVATO [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2019. Available at https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/SPRAVATO-pi.pdf. Accessed 7 October, 2025."},{"key":"9975_CR22","doi-asserted-by":"publisher","unstructured":"Wilkinson S, Howard D, Busch S. Psychiatric Practice Patterns and Barriers to Adoption of Esketamine. JAMA, September 2019; 322:11. Available at https:\/\/https:\/\/doi.org\/10.1001\/jama.2019.10728. Accessed 11 January, 2025.","DOI":"10.1001\/jama.2019.10728"},{"key":"9975_CR23","doi-asserted-by":"publisher","unstructured":"Ross E, Soeteman D, Cost Effectiveness of Esketamine Nasal Spray for Patients with Treatment-Resistant Depression in the United States, Psychiatric Services. 2020;71(10): 988\u2013997. Available at https:\/\/https:\/\/doi.org\/10.1176\/appi.ps.201900625. Accessed 11 January, 2025.","DOI":"10.1176\/appi.ps.201900625"},{"key":"9975_CR24","doi-asserted-by":"publisher","unstructured":"Brendle M, Robison R, Malone D. Cost-effectiveness of esketamine nasal spray compared to IV ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates. Journal of Affective Disorders, 2022;319:388\u2013396. Available at https:\/\/https:\/\/doi.org\/10.1016\/j.jad.2022.09.083. Accessed 11 January, 2025.","DOI":"10.1016\/j.jad.2022.09.083"}],"container-title":["The Journal of Behavioral Health Services & Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11414-025-09975-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11414-025-09975-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11414-025-09975-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:38:40Z","timestamp":1791826720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11414-025-09975-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9975"],"URL":"https:\/\/doi.org\/10.1007\/s11414-025-09975-x","relation":{},"ISSN":["1094-3412","1556-3308"],"issn-type":[{"value":"1094-3412","type":"print"},{"value":"1556-3308","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,19]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest or disclosures to declare.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}